Across TCGA pan-cancer cohorts, PRMT3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRMT3 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRMT3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRMT3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where PRMT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.765	0.428	.011	18	view →
PDAC	OS	Median	III,IV	0.220	0.653	.003	18	view →
CCRCC	DFS	Tertile	III,IV	0.281	0.599	.014	13	view →
LUAD	DFS	Tertile	II,III,IV	0.982	0.701	.009	11	view →
LSCC	DFS	Tertile	II,III,IV	0.896	0.543	.012	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PRMT3 tumor-vs-normal RNA expression · all PRMT3 data types